User login
Key clinical point: Patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) significantly benefitted from neoadjuvant chemotherapy with intense dose-dense epirubicin, paclitaxel and cyclophosphamide (iddPEC) vs paclitaxel plus non-pegylated liposomal doxorubicin (PM) plus carboplatin ([Cb], triple-negative BC only).
Major finding: Although the 4-year invasive disease-free survival (iDFS; P log-rank = .334) and overall survival (OS, P log-rank = .637) was not significantly different between iddEPC vs PM(Cb) arms in the entire cohort, the subgroup of patients with HR+/HER-2-, BC, showed significantly improved iDFS (hazard ratio [HR], 2.11; P log-rank = .025) and OS (HR, 3.26; P log-rank = .029).with iddEPC.
Study details: Findings are from phase 3 GeparOcto trial including 961 patients with high-risk early BC, who were randomly assigned 1:1 to receive iddEPC or PM(Cb), of which 706 patients completed treatment.
Disclosures: This study was funded by Roche, Amgen, TEVA, and Vifor. The authors reported receiving research grants, personal fees, consulting fees, honoraria and/ or travel support from the above companies and other sources.
Source: Schneeweiss A et al. Eur J Cancer. 2021 Nov 17. doi: 10.1016/j.ejca.2021.10.011.
Key clinical point: Patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) significantly benefitted from neoadjuvant chemotherapy with intense dose-dense epirubicin, paclitaxel and cyclophosphamide (iddPEC) vs paclitaxel plus non-pegylated liposomal doxorubicin (PM) plus carboplatin ([Cb], triple-negative BC only).
Major finding: Although the 4-year invasive disease-free survival (iDFS; P log-rank = .334) and overall survival (OS, P log-rank = .637) was not significantly different between iddEPC vs PM(Cb) arms in the entire cohort, the subgroup of patients with HR+/HER-2-, BC, showed significantly improved iDFS (hazard ratio [HR], 2.11; P log-rank = .025) and OS (HR, 3.26; P log-rank = .029).with iddEPC.
Study details: Findings are from phase 3 GeparOcto trial including 961 patients with high-risk early BC, who were randomly assigned 1:1 to receive iddEPC or PM(Cb), of which 706 patients completed treatment.
Disclosures: This study was funded by Roche, Amgen, TEVA, and Vifor. The authors reported receiving research grants, personal fees, consulting fees, honoraria and/ or travel support from the above companies and other sources.
Source: Schneeweiss A et al. Eur J Cancer. 2021 Nov 17. doi: 10.1016/j.ejca.2021.10.011.
Key clinical point: Patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) significantly benefitted from neoadjuvant chemotherapy with intense dose-dense epirubicin, paclitaxel and cyclophosphamide (iddPEC) vs paclitaxel plus non-pegylated liposomal doxorubicin (PM) plus carboplatin ([Cb], triple-negative BC only).
Major finding: Although the 4-year invasive disease-free survival (iDFS; P log-rank = .334) and overall survival (OS, P log-rank = .637) was not significantly different between iddEPC vs PM(Cb) arms in the entire cohort, the subgroup of patients with HR+/HER-2-, BC, showed significantly improved iDFS (hazard ratio [HR], 2.11; P log-rank = .025) and OS (HR, 3.26; P log-rank = .029).with iddEPC.
Study details: Findings are from phase 3 GeparOcto trial including 961 patients with high-risk early BC, who were randomly assigned 1:1 to receive iddEPC or PM(Cb), of which 706 patients completed treatment.
Disclosures: This study was funded by Roche, Amgen, TEVA, and Vifor. The authors reported receiving research grants, personal fees, consulting fees, honoraria and/ or travel support from the above companies and other sources.
Source: Schneeweiss A et al. Eur J Cancer. 2021 Nov 17. doi: 10.1016/j.ejca.2021.10.011.